Poor air affects you even if you don't smell wildfire smoke: Air pollution explained
The Shasta County Air Quality Management District and Shasta County Health and Human Services Agency advised people — especially those with health issues — to stay indoors when air is smoky.
However, just because you don't smell smoke doesn't mean the air is clean, according to the U.S. Environmental Protection Agency.
Here's where Shasta County's air is smokiest and how air can be polluted even without that smoke smell.
While smoke can fill the air at any time, according to forecasters, Redding, Shasta Lake and Anderson will get more smoke as it settles into the valley at night and early in the mornings, public health said.
Areas most affected by Green Fire smoke are Bella Vista, Palo Cedro, Shingletown, Round Mountain, Big Bend and Burney, according to the county.
Note to readers: If you appreciate the work we do here at the Redding Record Searchlight, please consider subscribing yourself or giving the gift of a subscription to someone you know.
While wildfire smoke is unhealthy, people and animals are also at health risk from what they can't smell.
Fires send a mixture of smoke and tiny particles called PM 2.5 — particulate matter — into the air. When you smell smoke, you're actually smelling just the gases, not the particles, said University of California, San Francisco pulmonologist Dr. John Balmes, an expert on the respiratory and cardiovascular effects of air pollution. Gases and PM 2.5 are side-by-side at the site of a fire, but the particles waft higher into the air at a short distance from the flames.
That's why you can have bad air — air high in PM 2.5 — without smelling smoke or gases.
PM 2.5 contains "microscopic solids or liquid droplets that are so small, they can be inhaled and cause serious health problems,' according to the EPA's PM 2.5 pollution website.
Air quality scientists measure the amount of PM 2.5 in the air. When air quality is ranked "unhealthy," it means there's enough PM 2.5 in the air to cause health problems, according to AirNow.
The particulates "have the ability to get deep into the lung,' Balmes said. 'They cause inflammation, which is the response of the body to injury of any type. When you breathe in these fine particles to your lungs it causes injury. Once there's inflammation in the lungs, it can exacerbate lung (and) heart conditions.'
When air is unhealthy, everyone should reduce the amount of time they spend outdoors if they can, the EPA warns. However, some people are especially vulnerable to the effects of bad air.
When air quality is ranked "unhealthy for vulnerable groups" it means PM 2.5 are at levels that can cause problems for people with medical conditions, especially respiratory issues like asthma and heart or lung disease. Certain age groups — older adults, children and teens — are also vulnerable to problems from bad air, according to the EPA.
When PM 2.5 levels are so high they can hurt anyone, air is ranked "unhealthy", "very unhealthy" or "hazardous" by the EPA. In these cases, everyone should limit prolonged exposure.
The EPA's website at AirNow.gov can tell you how much PM 2.5 is in your air. It also offers health and lifestyle advice based on that result.
Here's what public health branches recommend people do when air is polluted.
Limit outdoor activities.
Remain indoors with the windows and doors closed.
Turn on an air conditioner with a re-circulation setting, like in a vehicle.
If you do go out, choose less strenuous outdoor activities. For example, go for a walk instead of a run.
To learn more about particulate matter go to the California Air Resources Board website at arb.ca.gov/resources/inhalable-particulate-matter-and-health.
Jessica Skropanic is a features reporter for the Record Searchlight/USA Today Network. She covers science, arts, social issues and news stories. Follow her on Twitter @RS_JSkropanic and on Facebook. Join Jessica in the Get Out! Nor Cal recreation Facebook group. To support and sustain this work, please subscribe today. Thank you.
This article originally appeared on Redding Record Searchlight: Don't let poor air quality, wildfire smoke affect you, Californians
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
13 minutes ago
- Fox News
Swallow this pill to learn about your gut and health
The future of gut health monitoring has arrived, thanks to researchers at the California Institute of Technology. Caltech's new invention, PillTrek, is a wireless smart capsule for gut health monitoring that delivers real-time insights from inside your gastrointestinal tract. This swallowable device promises to make invasive procedures a thing of the past, offering convenience and continuous data that traditional methods simply cannot match. PillTrek stands out because it combines miniature size with advanced technology. The capsule measures only 7 millimeters in diameter and 25 millimeters in length, making it smaller than most capsule endoscopes. Despite its tiny size, PillTrek contains a suite of sensors that can detect electrolytes, metabolites, glucose, hormones such as serotonin and dopamine, pH, ionic strength and temperature. The design allows doctors to swap out sensors based on the specific biomarkers they need to monitor, making PillTrek a flexible and powerful diagnostic tool. The capsule transmits data wirelessly as it moves through the digestive system, providing real-time updates on a patient's gut health. Unlike endoscopy or CT scans, PillTrek does not require hospital visits or recovery time. Its low-power electronics enable it to operate for extended periods, delivering continuous monitoring that traditional methods cannot provide. Scientists now understand that the gastrointestinal tract influences far more than just digestion. The gut plays a critical role in hormone production, immune function and even mental health. Monitoring gut biomarkers helps identify conditions such as metabolic syndrome, which increases the risk of heart disease and diabetes, as well as inflammation and hormonal imbalances. Traditional diagnostic methods like biopsies and fecal analysis are invasive, costly, and do not offer real-time results. PillTrek's wireless smart capsule for gut health monitoring changes this landscape by providing immediate, actionable data from inside the body. Caltech's team developed PillTrek by leveraging breakthroughs in sensor materials and electrochemical measurement techniques. The capsule's reconfigurable design means that doctors can adapt it to monitor new biomarkers as medical science advances. Researchers tested PillTrek in animal models, successfully measuring pH, temperature, glucose and serotonin levels in real time. The capsule's sensors are inexpensive and mass-producible, making this technology accessible for widespread clinical use. The Caltech team continues to refine PillTrek, aiming to make it even smaller and more energy efficient. Future versions may use wireless power transfer and next-generation electronics, extending the capsule's lifespan and expanding its medical applications. As technology advances, PillTrek could become a standard tool for diagnosing and managing chronic GI conditions. While PillTrek offers exciting possibilities for non-invasive, real-time gut health monitoring, it also raises important questions. Some patients and healthcare professionals may have concerns about the safety of ingesting electronic devices, even if they are small and designed for medical use. Potential issues include the risk of the capsule getting stuck, allergic reactions to materials, or unforeseen interactions with other medical conditions. Data privacy is another consideration. As PillTrek transmits sensitive health information wirelessly, robust security measures are essential to protect patient data from unauthorized access. Additionally, long-term studies are needed to fully understand any potential side effects or complications. As with any new medical technology, regulatory approval and thorough clinical testing will play a crucial role in ensuring PillTrek's safety and effectiveness for widespread use. Breakthroughs like PillTrek signal a new era in non-invasive, real-time gut health monitoring. This wireless smart capsule for gut health monitoring offers doctors and patients an unprecedented look inside the digestive system, making diagnosis and treatment more precise and less invasive than ever before. The future of personalized medicine could soon be as simple as swallowing a pill. If you could track your gut health in real time by swallowing a smart capsule, would you? Let us know by writing us at Sign up for my FREE CyberGuy Report Get my best tech tips, urgent security alerts, and exclusive deals delivered straight to your inbox. Plus, you'll get instant access to my Ultimate Scam Survival Guide - free when you join my Copyright 2025 All rights reserved.
Yahoo
an hour ago
- Yahoo
Genentech Provides Update on Supplemental Biologics License Application for Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
SOUTH SAN FRANCISCO, Calif., July 18, 2025--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for Genentech's supplemental Biologics License Application (sBLA) for Columvi® (glofitamab-gxbm) in combination with gemcitabine and oxaliplatin (GemOx) for the treatment of people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are not candidates for autologous stem cell transplant. Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the U.S. patient population. STARGLO was also intended as a postmarketing confirmatory study to convert the accelerated approval of Columvi in third-line or later DLBCL in the U.S. to full approval. Columvi remains under accelerated approval for people with third-line or later DLBCL. Discussions with the FDA are ongoing to confirm the Phase III SKYGLO study investigating Columvi in combination with Polivy® (polatuzumab vedotin-piiq), Rituxan® (rituximab), cyclophosphamide, doxorubicin and prednisone for patients with previously untreated large B-cell lymphoma as the new postmarketing requirement. "While we are disappointed with this outcome, we remain confident in the data supporting the value of Columvi for U.S. patients who have relapsed following initial treatment, and its key role as monotherapy in the third-line setting," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. "We are committed to bringing Columvi to more people living with lymphoma and are actively exploring its potential in additional treatment settings, including as frontline therapy." "For patients with this aggressive form of lymphoma, effective treatment after relapse is paramount. The STARGLO study showed that Columvi-GemOx significantly improves overall survival and could have a positive impact for patients earlier in their treatment journey. This regimen is already approved in over 35 countries, which underscores the urgent need it addresses," said Jeremy Abramson, M.D., director, Jon and Jo Ann Hagler Center for Lymphoma at the Massachusetts General Hospital Cancer Center, and principal investigator of the STARGLO study. Based on the STARGLO data, this Columvi combination is approved in more than 35 countries, including in the EU, and recommended in clinical practice guidelines including the U.S. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®).† Data has been submitted to other health authorities around the world for approval consideration. Columvi monotherapy has been approved for use in R/R DLBCL after two or more prior lines of therapy in more than 60 countries worldwide. The sBLA is based on results from the Phase III STARGLO study which showed a statistically significant and clinically meaningful 41% reduction in the risk of death (hazard ratio=0.59, 95% confidence interval: 0.40–0.89, p=0.011) in patients treated with Columvi in combination with GemOx. Results were published in The Lancet and two-year follow-up data from the study were presented at the 61st American Society of Clinical Oncology Annual Meeting from May 30 – June 3, 2025, where improvements in primary and secondary endpoints were sustained. †NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. About the STARGLO study The STARGLO study [GO41944; NCT04408638] is a Phase III, multicenter, open-label, randomized study evaluating the efficacy and safety of Columvi® (glofitamab-gxbm) in combination with gemcitabine plus oxaliplatin (GemOx) versus Rituxan® (rituximab) in combination with GemOx in patients with relapsed or refractory diffuse large B-cell lymphoma who have received at least one prior line of therapy and who are not candidates for autologous stem cell transplant, or who have received two or more prior lines of therapy. Preclinical research indicated an increased antitumor effect when combining Columvi with GemOx over GemOx alone, so the STARGLO study was initiated to further explore the potential complementary effects of the treatment combination. Outcome measures include overall survival (primary endpoint), progression-free survival, complete response rate, objective response rate, duration of objective response (secondary endpoints), and safety and tolerability. About Columvi® (glofitamab-gxbm) Columvi is a CD20xCD3 T-cell engaging bispecific antibody designed to target CD3 on the surface of T cells and CD20 on the surface of B cells. Columvi was designed with a novel 2:1 structural format. This T-cell-engaging bispecific antibody is engineered to have one region that binds to CD3, a protein on T cells, a type of immune cell, and two regions that bind to CD20, a protein on B cells, which can be healthy or malignant. This dual-targeting brings the T cell in close proximity to the B cell, activating the release of cancer cell-killing proteins from the T cell. Columvi is part of Genentech's broad and industry-leading CD20xCD3 T-cell-engaging bispecific antibody clinical development program, which aims to provide tailored treatment options that suit the diverse needs, preferences, and experiences of people with blood cancers and healthcare systems. Genentech is investigating Columvi as a monotherapy and in combination with other medicines for the treatment of diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma. As part of Genentech's efforts to elevate treatment standards in the earlier stages of DLBCL, where there is the best opportunity to improve long-term outcomes and prevent relapse, Columvi is also being investigated in combination with other medicines in previously untreated DLBCL in the Phase III SKYGLO study [GO44145; NCT06047080]. About diffuse large B-cell lymphoma (DLBCL) Diffuse large B-cell lymphoma (DLBCL) is an aggressive (fast-growing) blood cancer and is the most common form of non-Hodgkin's lymphoma in the U.S. Approximately 160,000 people worldwide are diagnosed with DLBCL each year, with comparable incidence rates across regions. Medical practices, including pathological classification, diagnosis, staging, initial treatment and relapse management, are similarly approached worldwide. While it is generally responsive to treatment in the frontline, as many as 40% of people will relapse or have refractory disease, at which time salvage therapy options are limited and survival is short. Improving treatments earlier in the course of the disease and providing much-needed alternative options could help to improve long-term outcomes. Columvi U.S. Indication Columvi (glofitamab-gxbm) is a prescription medicine to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) or large B-cell lymphoma (LBCL) that has come back (relapsed) or that did not respond to previous treatment (refractory), and who have received 2 or more prior treatments for their cancer. It is not known if Columvi is safe and effective in children. The conditional approval of Columvi is based on response rate and durability of response. There are ongoing studies to establish how well the drug works. What is the most important information I should know about Columvi? Columvi can cause Cytokine Release Syndrome (CRS), a serious side effect that is common during treatment with Columvi, and can also be serious and lead to death. Call your healthcare provider or get emergency medical help right away if you develop any signs or symptoms of CRS, including: fever of 100.4°F (38°C) or higher chills or shaking fast or irregular heartbeat dizziness or light-headedness trouble breathing shortness of breath Due to the risk of CRS, you will receive Columvi on a "step-up dosing schedule". A single dose of a medicine called obinutuzumab will be given to you on the first day of your first treatment cycle (Day 1 of Cycle 1). You will start the Columvi step-up dosing schedule a week after the obinutuzumab dose. The step-up dosing schedule is when you receive smaller "step-up" doses of Columvi on Day 8 and Day 15 of Cycle 1. This is to help reduce your risk of CRS. You should be hospitalized during your infusion and for 24 hours after receiving the first step-up dose on Day 8. You should be hospitalized during your infusion and for 24 hours after receiving the second step-up dose on Day 15 if you experienced CRS during the first step-up dose. You will receive your first full dose of Columvi a week after the second step-up dose (this will be Day 1 of Cycle 2). If your dose of Columvi is delayed for any reason, you may need to repeat the "step-up dosing schedule". If you had more than mild CRS with your previous dose of Columvi, you should be hospitalized during and for 24 hours after receiving your next dose of Columvi. Before each dose of Columvi, you will receive medicines to help reduce your risk of CRS and infusion-related reactions. Your healthcare provider will monitor you for CRS during treatment with Columvi and may treat you in a hospital if you develop signs and symptoms of CRS. Your healthcare provider may temporarily stop or completely stop your treatment with Columvi if you have severe side effects. Carry the Columvi Patient Wallet Card with you at all times and show it to all of your healthcare providers. The Columvi Patient Wallet Card lists the signs and symptoms of CRS you should get emergency medical help for right away. What are the possible side effects of Columvi? Columvi may cause serious side effects, including: Cytokine Release Syndrome. Neurologic problems. Columvi can cause serious neurologic problems that may lead to death. Your healthcare provider will monitor you for neurologic problems during treatment with Columvi. Your healthcare provider may also refer you to a healthcare provider who specializes in neurologic problems. Tell your healthcare provider right away if you develop any signs or symptoms of neurologic problems, including: headache confusion and disorientation difficulty paying attention or understanding things trouble speaking sleepiness memory problems numbness, tingling, or weakness of the hands or feet dizziness shaking (tremors) Serious Infections. Columvi can cause serious infections that may lead to death. Your healthcare provider will monitor you for signs and symptoms of infection and treat you as needed. Tell your healthcare provider right away if you develop any signs of an infection, including: fever, chills, weakness, cough, shortness of breath, or sore throat. Growth in your tumor or worsening of tumor related problems (tumor flare). Tell your healthcare provider if you get any of these signs or symptoms of tumor flare: tender or swollen lymph nodes pain or swelling at the site of the tumor chest pain cough trouble breathing The most common side effects of Columvi include: CRS, muscle and bone pain, rash, and tiredness. The most common severe abnormal lab test results with Columvi include: decreased white blood cells, decreased phosphate (an electrolyte), increased uric acid levels, and decreased fibrinogen (a protein that helps with blood clotting). Your healthcare provider may temporarily stop or completely stop treatment with Columvi if you develop certain side effects. Before receiving Columvi, tell your healthcare provider about all of your medical conditions, including if you: have an infection have kidney problems are pregnant or plan to become pregnant. Columvi may harm your unborn baby Females who are able to become pregnant: Your healthcare provider should do a pregnancy test before you start treatment with Columvi. You should use effective birth control (contraception) during treatment and for 1 month after your last dose of Columvi. Talk to your healthcare provider about what birth control method is right for you during this time. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Columvi. are breastfeeding or plan to breastfeed. Columvi may pass into your breast milk. Do not breastfeed during treatment and for 1 month after your last dose of Columvi. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. What should I avoid while receiving Columvi? Do not drive, operate heavy machinery, or do other dangerous activities if you develop dizziness, confusion, shaking (tremors), sleepiness, or any other symptoms that impair consciousness until your signs and symptoms go away. These may be signs and symptoms of neurologic problems. These are not all the possible side effects of Columvi. Talk to your health care provider for more information about the benefits and risks of Columvi. You may report side effects to the FDA at (800) FDA-1088 or You may also report side effects to Genentech at (888) 835-2555. Please see Important Safety Information, including Serious Side Effects, as well as the Columvi full Prescribing Information and Medication Guide or visit About Polivy® (polatuzumab vedotin-piiq) Polivy is a first-in-class anti-CD79b antibody-drug conjugate (ADC). The CD79b protein is expressed in the majority of B cells, an immune cell impacted in some types of non-Hodgkin lymphoma (NHL), making it a promising target for the development of new therapies. Polivy binds to cancer cells such as those expressing CD79b and destroys these B cells through the delivery of an anti-cancer agent, which is thought to minimize the effects on normal cells. Polivy is being developed by Genentech using Pfizer ADC technology and is currently being investigated for the treatment of several types of NHL. Polivy U.S. Indication Polivy is a prescription medicine used with other medicines (a rituximab product, cyclophosphamide, doxorubicin, and prednisone) as a first treatment for adults who have moderate to high risk diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL). Polivy is a prescription medicine used with other medicines, bendamustine and a rituximab product, to treat DLBCL in adults who have progressed after at least 2 prior therapies. Important Safety Information Possible serious side effects Everyone reacts differently to Polivy therapy, so it's important to know what the side effects are. Some people who have been treated with Polivy have experienced serious to fatal side effects. Your doctor may stop or adjust your treatment if any serious side effects occur. Be sure to contact your healthcare team if there are any signs of these side effects. Nerve problems in your arms and legs: This may happen as early as after your first dose and may worsen with every dose. Your doctor will monitor for signs and symptoms, such as changes in your sense of touch, numbness or tingling in your hands or feet, nerve pain, burning sensation, any muscle weakness, or changes to your walking pattern Infusion-related reactions: You may experience fever, chills, rash, breathing problems, low blood pressure, or hives within 24 hours of your infusion Low blood cell counts: Treatment with Polivy can cause severe low blood cell counts. Your doctor will monitor your blood counts throughout treatment with Polivy Infections: If you have a fever of 100.4°F (38°C) or higher, chills, cough, or pain during urination, contact your healthcare team. Your doctor may also give you medication before giving you Polivy, which may prevent some infections Rare and serious brain infections: Your doctor will monitor closely for signs and symptoms of these types of infections. Contact your doctor if you experience confusion, dizziness or loss of balance, trouble talking or walking, or vision changes Tumor lysis syndrome: Caused by the fast breakdown of cancer cells. Signs include nausea, vomiting, diarrhea, and lack of energy Potential harm to liver: Some signs include tiredness, weight loss, pain in the abdomen, dark urine, and yellowing of your skin or the white part of your eyes. You may be at higher risk if you already had liver problems or you are taking other medication Side effects seen most often The most common side effects during treatment were Nerve problems in arms and legs Nausea Tiredness or lack of energy Diarrhea Constipation Hair loss Redness and sores of the lining of the mouth, lips, throat, and digestive tract Polivy may lower your red or white blood cell counts and increase uric acid levels. Polivy may not be for everyone. Talk to your doctor if you are Pregnant or think you are pregnant: Data have shown that Polivy may harm your unborn baby Planning to become pregnant: Women should avoid getting pregnant while taking Polivy. Women should use effective contraception during treatment and for 3 months after their last Polivy treatment. Men taking Polivy should use effective contraception during treatment and for 5 months after their last Polivy treatment Breastfeeding: Women should not breastfeed while taking Polivy and for 2 months after the last dose These may not be all the side effects. Talk to your healthcare provider for more information about the benefits and risks of Polivy treatment. You may report side effects to the FDA at (800) FDA-1088 or You may also report side effects to Genentech at (888) 835-2555. Please see the full Prescribing Information and visit for additional Important Safety Information. About Genentech in hematology For more than 20 years, Genentech has been developing medicines with the goal to redefine treatment in hematology. Today, we're investing more than ever in our effort to bring innovative treatment options to people with diseases of the blood. For more information visit About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Genentech Group, has headquarters in South San Francisco, California. For additional information about the company, please visit View source version on Contacts Media Contact:Kristen Ingram, (650) 467-6800 Advocacy Contact:Catherine Creme Henry, (202) 258-8228 Investor Contacts:Loren Kalm, (650) 225-3217Bruno Eschli, +41 61 687 5284 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Michael Madsen cremated, more details about actor's death emerge
Actor Michael Madsen was cremated this week following his death earlier his month, about which more details are now emerging. A number of conditions, including cardiomyopathy — which makes it more difficult for the heart to pump blood throughout the body — along with coronary artery disease and chronic alcoholism all contributed to the cardiac arrest that ultimately killed the 67-year-old 'Kill Bill' star, according to a death certificate issued by Los Angeles County Medical Examiner and obtained by TMZ on Thursday. Thromboembolic disease, when vessels or arteries are blocked by blood clots, was also identified as a significant contributing factor. The death certificate shows that Madsen, who'd reportedly gotten sober in recent months, died less than two months after undergoing coronary angiography, which uses X-rays to look at the heart's blood vessels, per Mayo Clinic. Madsen's manager Ron Smith previously confirmed to NBCLA that Madsen died at his Malibu, California, home on July 3 from cardiac arrest. Days later, Madsen's cardiologist told the outlet that heart disease and alcoholism would be listed as contributing factors to his heart failure. Sister and fellow actor, Oscar nominee Virginia Madsen, remembered her big brother as 'half legend, half lullaby' — 'etched in contradiction, tempered by love that left its mark.' Madsen is survived by four children, including his son Christian, who is also an actor. He was predeceased by one of his sons, Hudson, who died by suicide in 2022.
